Clinical Trials Logo

Neoplasm, Colorectal clinical trials

View clinical trials related to Neoplasm, Colorectal.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06033976 Recruiting - Clinical trials for Neoplasm, Colorectal

Endoscopic Submucosal Dissection Registry

ESDREG
Start date: January 1, 2021
Phase:
Study type: Observational [Patient Registry]

This is a patient registry for all cases of pre-neoplastic or early neoplastic digestive tract lesions treated with curative intention by endoscopic submucosal dissection (ESD) technique.

NCT ID: NCT05512260 Recruiting - Neoplasm, Breast Clinical Trials

Development, Implementation and Evaluation of an Individual Decision Aid in Swedish Cancer Screening Programs

BESTa
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Background: Sweden has a long tradition of organized national population-based screening programs. Participation rates differ between programs and regions, are relatively high in some groups, but lower in other. To apply an equity perspective on screening, it is desired that individuals make an informed decision on knowledge rather than ignorance, misconceptions, or fear. Decision Aids (DAs) are set to deliver information about different health care options and to help individuals make visible values connected to the options available. DAs are not meant to guide individuals to choose one option over the another. The advantage of an individual Decision Aid (iDA) is that individuals gain knowledge on cancer and screening entering one webpage with possibility to communicate with health professionals and thereafter make their decision regarding participate. The primary objective is therefore to develop and implement a web-based iDA for individuals invited to cancer screening in Sweden. The secondary objective is to evaluate the implemented web-based iDA. Methods: This study has an evaluative approach with both a process-, an implementation and an outcome evaluation. Multiple methods will be used including patient reported data, focus group discussions and individual interviews using the think aloud technique. The project is based on the framework from The International Patient Decision Aid Standards (IPDAS) and the proposed model development process for DAs as presented by Coulter et al. Individuals aged 23-74, including women aged (the cervical- and breast- and bowel cancer screening module) and men aged (the bowel cancer screening module), will be included in the developmental process. Efforts will be made to recruit participants with disabilities, who live outside society and who are foreign born. Discussion: To the best of our knowledge the present study is the first aiming at developing an iDA for usage in Swedish context, The iDA is intended to contribute so that individuals invited to screening base their decision on knowledge and with a clear picture of their values and preferences, rather than ignorance, misconceptions, or fear. Furthermore, the iDA is expected to increase knowledge and raise awareness in general about cancer and cancer screening in society.

NCT ID: NCT05014399 Recruiting - Clinical trials for Cognitive Impairment

Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy

Chemo Brain
Start date: September 20, 2021
Phase:
Study type: Observational

The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer Institute. This information will be used to identify helpful tests to diagnose individuals at risk for developing difficulties with thinking and memory due to their cancer treatments.

NCT ID: NCT04566614 Recruiting - Clinical trials for Biliary Tract Neoplasms

Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies

PREVAILctDNA
Start date: June 18, 2020
Phase:
Study type: Observational

The purpose of this study is to investigate the feasibility of using ctDNA to support cancer diagnosis and risk stratification where invasive aerosol generating testing (and/or tissue biopsy) is challenging due to infection risk, technical impracticalities and resource limitations, such as during the COVID-19 pandemic and the subsequent recovery period.